184 related articles for article (PubMed ID: 38400668)
21. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.
Zettler ME
Expert Rev Anticancer Ther; 2022 Mar; 22(3):317-321. PubMed ID: 35051348
[TBL] [Abstract][Full Text] [Related]
22. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL; Hoes LR; van der Wijngaart H; van Berge Henegouwen JM; van Werkhoven E; Roepman P; Schilsky RL; de Leng WWJ; Huitema ADR; Nuijen B; Nederlof PM; van Herpen CML; de Groot DJA; Devriese LA; Hoeben A; de Jonge MJA; Chalabi M; Smit EF; de Langen AJ; Mehra N; Labots M; Kapiteijn E; Sleijfer S; Cuppen E; Verheul HMW; Gelderblom H; Voest EE
Nature; 2019 Oct; 574(7776):127-131. PubMed ID: 31570881
[TBL] [Abstract][Full Text] [Related]
23. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
24. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
25. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
[TBL] [Abstract][Full Text] [Related]
26. Educational paper. The development of new therapies for pediatric oncology.
Horton TM; Berg SL
Eur J Pediatr; 2011 May; 170(5):555-9. PubMed ID: 21190039
[TBL] [Abstract][Full Text] [Related]
27. Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.
Carreras MJ; Tomás-Guillén E; Farriols A; Renedo-Miró B; Valdivia C; Vidal J; Saura C; Carles J; Felip E; Gorgas MQ; Tabernero J; Monterde J
Curr Oncol; 2023 Aug; 30(9):7984-8004. PubMed ID: 37754495
[TBL] [Abstract][Full Text] [Related]
28. Barriers to Medication Access in Pediatric Oncology in the United States.
Kelly MJ; Sung L; Dickens DS
J Pediatr Hematol Oncol; 2019 May; 41(4):286-288. PubMed ID: 30124549
[TBL] [Abstract][Full Text] [Related]
29. Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement.
Sehdev SR; Rawson NSB; Aseyev OI; Buick CJ; Butler MO; Edwards S; Gill S; Gotfrit JM; Hsia CC; Juergens RA; Manna M; McCarthy JS; Mukherjee SD; Snow SL; Spadafora S; Stewart DJ; Wentzell JR; Wong RPW; Zalewski PG
Curr Oncol; 2024 Mar; 31(4):1803-1816. PubMed ID: 38668039
[TBL] [Abstract][Full Text] [Related]
30. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
31. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
[TBL] [Abstract][Full Text] [Related]
32. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
33. Landscape of early clinical trials for childhood and adolescence cancer in Spain.
Bautista F; Gallego S; Cañete A; Mora J; Diaz de Heredia C; Cruz O; Fernández JM; Rives S; Madero L; Castel V; Cela ME; Ramírez G; Sábado C; Acha T; Astigarraga I; Sastre A; Muñoz A; Guibelalde M; Moreno L
Clin Transl Oncol; 2016 Jul; 18(7):708-13. PubMed ID: 26489424
[TBL] [Abstract][Full Text] [Related]
34. Exploring Barriers to Pediatric Cancer Clinical Trials: The Role of a Networked, Just-in-Time Study Program.
Rivers Z; Hyde B; Ronski K; Stearns D; Toll S; Ritt K; Cooney M; Nimeiri H; Federman N; Kaneva K
Clin Ther; 2023 Nov; 45(11):1148-1150. PubMed ID: 37783645
[TBL] [Abstract][Full Text] [Related]
35. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
36. Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).
Smoragiewicz M; Adjei AA; Calvo E; Tabernero J; Marabelle A; Massard C; Tang J; de Vries EGE; Douillard JY; Seymour L;
Clin Cancer Res; 2020 Jun; 26(11):2461-2465. PubMed ID: 32086344
[TBL] [Abstract][Full Text] [Related]
37. Determinants of the Cancer Drug Funding Process in Canada.
Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
[TBL] [Abstract][Full Text] [Related]
38. New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.
Rossig C; Juergens H; Berdel WE
Pediatr Hematol Oncol; 2011 Oct; 28(7):539-55. PubMed ID: 21936619
[TBL] [Abstract][Full Text] [Related]
39. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
40. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]